ATE516041T1 - Synergistische zusammensetzungen mit fk-228 - Google Patents

Synergistische zusammensetzungen mit fk-228

Info

Publication number
ATE516041T1
ATE516041T1 AT05719967T AT05719967T ATE516041T1 AT E516041 T1 ATE516041 T1 AT E516041T1 AT 05719967 T AT05719967 T AT 05719967T AT 05719967 T AT05719967 T AT 05719967T AT E516041 T1 ATE516041 T1 AT E516041T1
Authority
AT
Austria
Prior art keywords
antitumor agent
antitumor
synergistic compositions
agent
dna
Prior art date
Application number
AT05719967T
Other languages
English (en)
Inventor
Yoshinori Naoe
Takeshi Inoue
Yasuhiko Kano
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE516041T1 publication Critical patent/ATE516041T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05719967T 2004-02-25 2005-02-25 Synergistische zusammensetzungen mit fk-228 ATE516041T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004050520 2004-02-25
US56607704P 2004-04-29 2004-04-29
PCT/JP2005/003689 WO2005079827A2 (en) 2004-02-25 2005-02-25 Antitumor agent

Publications (1)

Publication Number Publication Date
ATE516041T1 true ATE516041T1 (de) 2011-07-15

Family

ID=34889383

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05719967T ATE516041T1 (de) 2004-02-25 2005-02-25 Synergistische zusammensetzungen mit fk-228

Country Status (11)

Country Link
US (2) US7951780B2 (de)
EP (1) EP1718322B1 (de)
JP (1) JP4930055B2 (de)
AT (1) ATE516041T1 (de)
CA (1) CA2557540A1 (de)
CY (1) CY1111926T1 (de)
DK (1) DK1718322T3 (de)
PL (1) PL1718322T3 (de)
PT (1) PT1718322E (de)
SI (1) SI1718322T1 (de)
WO (1) WO2005079827A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1426054B1 (de) * 2001-08-21 2011-09-28 Astellas Pharma Inc. Medizinische verwendung eines histon-deacetylase-hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
JP2005521737A (ja) * 2002-04-05 2005-07-21 藤沢薬品工業株式会社 腎臓癌の治療のためのデプシペプチド
CA2519320A1 (en) * 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
EP2263694B1 (de) * 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumormittel, enthaltend den Histon-deacetylase-inhibitor FK228 und den Topoisomerase-II-Inhibitor Doxorubicin
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
AU2006318652A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the HDAC inhibitor FK228
CA2649877A1 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
JP2010514802A (ja) * 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンをベースとする癌の処置
JP2010514801A (ja) * 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンの精製
WO2010036404A2 (en) * 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
EP2366398A1 (de) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Krebstherapie mit einem Parvovirus in Kombination mit einem HDAC-Hemmer
EP3056201A1 (de) * 2010-06-07 2016-08-17 Abraxis BioScience, LLC Kombinationstherapieverfahren zur behandlung proliferativer erkrankungen
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106860872B (zh) * 2017-01-18 2019-03-22 上海交通大学 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0315810A (ja) * 1989-06-13 1991-01-24 Minolta Camera Co Ltd カメラ
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
JP2003513912A (ja) * 1999-11-10 2003-04-15 ワーナー−ランバート・カンパニー 組合せ化学療法
WO2001042282A1 (en) * 1999-12-08 2001-06-14 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
JP2004508049A (ja) 2000-09-01 2004-03-18 藤沢薬品工業株式会社 Ｆｒ９０１２２８物質の製造法
EP1355566B1 (de) * 2000-12-18 2012-11-28 Board Of Regents, The University Of Texas System Lokale regionale Chemotherapie und Radiotherapie, bei der ein in-situ-Hydrogel verwendet wird
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
EP1426054B1 (de) 2001-08-21 2011-09-28 Astellas Pharma Inc. Medizinische verwendung eines histon-deacetylase-hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
SK1102004A3 (sk) * 2001-08-31 2005-05-05 Bristol-Myers Squibb Company Liečivo na liečenie proliferačných ochorení a farmaceutická kompozícia na liečenie rakoviny
EP1293205A1 (de) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproinsäure und deren Derivate zur Kombinationsbehandlung von Krebs beim Menschen und zur Behandlung von Tumor-Metastasen und minimaler Resterkrankung
JP2005521737A (ja) 2002-04-05 2005-07-21 藤沢薬品工業株式会社 腎臓癌の治療のためのデプシペプチド
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
CA2519320A1 (en) 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
EP1638541B1 (de) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutisches mittel für ein weichteilsarkom
CA2472842C (en) 2003-07-22 2012-05-29 Honda Motor Co., Ltd. Working machine
EP2263694B1 (de) 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumormittel, enthaltend den Histon-deacetylase-inhibitor FK228 und den Topoisomerase-II-Inhibitor Doxorubicin
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent

Also Published As

Publication number Publication date
US20050187149A1 (en) 2005-08-25
DK1718322T3 (da) 2011-08-29
WO2005079827A3 (en) 2005-12-08
US7951780B2 (en) 2011-05-31
SI1718322T1 (sl) 2011-09-30
US20110160295A1 (en) 2011-06-30
JP2007524650A (ja) 2007-08-30
CA2557540A1 (en) 2005-09-01
CY1111926T1 (el) 2015-11-04
PL1718322T3 (pl) 2011-12-30
US8822422B2 (en) 2014-09-02
PT1718322E (pt) 2011-09-05
WO2005079827A2 (en) 2005-09-01
JP4930055B2 (ja) 2012-05-09
EP1718322A2 (de) 2006-11-08
EP1718322B1 (de) 2011-07-13

Similar Documents

Publication Publication Date Title
ATE516041T1 (de) Synergistische zusammensetzungen mit fk-228
MXPA06003222A (es) Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
PT1849470T (pt) Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
WO2007103510A3 (en) Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
NO20082298L (no) Kaliumkanalinhibitorer
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
WO2009074677A3 (en) Pyrazolotriazines
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
GB2437149B (en) Synergistic preservative systems and their use in cosmetic compositions.
WO2009156182A3 (de) Uracilderivate und deren verwendung
WO2006061258A3 (en) Cytotoxic agents comprising new taxanes
IL178727A (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
WO2008006883A3 (en) Benzopyranopyrazoles
EP2357003A4 (de) Zusammensetzung gegen krebs mit einem antitumorwirkstoff und einem stoff mit hemmender wirkung auf die l1cam-aktivität und -expression
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
WO2009047434A3 (fr) Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1718322

Country of ref document: EP